Phase I Multiple Ascending Dose Study for AZD 7268 in Healthy Volunteers

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: AZD7268

Study type: Interventional

Funder types: Industry

Identifiers

NCT00861718

D1151C00003

Details and patient eligibility

About

Multiple Ascending Dose Study

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Provision of Informed Consent

• Healthy male subjects and female subjects (of non-child bearing potential)

  • with suitable veins for cannulation or repeated venipuncture

Exclusion criteria

• Inability to understand or cooperate with given information
• Any positive result on screening for human immune deficiency virus (HIV), Hepatitis B, or Hepatitis C test
• History of seizure (including infancy febrile seizures) or family history of seizure

Trial design

40 participants in 2 patient groups, including a placebo group

AZD7268

Experimental group

Treatment:

Drug: AZD7268

Drug: AZD7268

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo